Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 May;24(5):551-555.
doi: 10.1038/s41591-018-0015-9. Epub 2018 May 7.

MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency

Affiliations
Clinical Trial

MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency

Karine Clément et al. Nat Med. 2018 May.

Abstract

Genetic defects underlying the melanocortin-4 receptor (MC4R) signaling pathway lead to severe obesity. Three severely obese LEPR-deficient individuals were administered the MC4R agonist setmelanotide, resulting in substantial and durable reductions in hyperphagia and body weight over an observation period of 45-61 weeks. Compared to formerly developed and tested MC4R agonists, setmelanotide has the unique capability of activating nuclear factor of activated T cell (NFAT) signaling and restoring function of this signaling pathway for selected MC4R variants. Our data demonstrate the potency of setmelanotide in treatment of individuals with diverse MC4R-related pathway deficiencies.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Farooqi, I. S. & O’Rahilly, S. J. Endocrinol. 223, T63–T70 (2014). - DOI
    1. Krishna, R. et al. Clin. Pharmacol. Ther. 86, 659–666 (2009). - DOI
    1. Farooqi, I. S. et al. N. Engl. J. Med. 341, 879–884 (1999). - DOI
    1. Clément, K. et al. Nature 392, 398–401 (1998). - DOI
    1. Jackson, V. M., Price, D. A. & Carpino, P. A. Expert Opin. Investig. Drugs 23, 1055–1066 (2014). - DOI

Publication types